$0.60
3.39% today
Nasdaq, Apr 01, 07:19 pm CET
ISIN
US00166B1052
Symbol
ALXO

Alx Oncology Holdings Inc Stock price

$0.62
-0.48 43.36% 1M
-1.20 65.77% 6M
-1.05 62.69% YTD
-10.40 94.35% 1Y
-16.28 96.31% 3Y
-29.38 97.92% 5Y
-29.38 97.92% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.03 4.90%
ISIN
US00166B1052
Symbol
ALXO
Sector
Industry

Key metrics

Market capitalization $33.26m
Enterprise Value $-77.52m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.63
P/B ratio (TTM) P/B ratio 0.29
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-142.47m
Free Cash Flow (TTM) Free Cash Flow $-122.36m
Cash position $127.76m
EPS (TTM) EPS $-2.61
P/E forward negative
Short interest 20.56%
Show more

Is Alx Oncology Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Alx Oncology Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Alx Oncology Holdings Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Alx Oncology Holdings Inc forecast:

Buy
71%
Hold
29%

Financial data from Alx Oncology Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.87 0.87
40% 40%
-
-0.87 -0.87
40% 40%
-
- Selling and Administrative Expenses 24 24
5% 5%
-
- Research and Development Expense 116 116
18% 18%
-
-142 -142
16% 16%
-
- Depreciation and Amortization 0.87 0.87
40% 40%
-
EBIT (Operating Income) EBIT -142 -142
16% 16%
-
Net Profit -135 -135
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Alx Oncology Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alx Oncology Holdings Inc Stock News

Neutral
GlobeNewsWire
26 days ago
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI
Neutral
GlobeNewsWire
27 days ago
Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash ru...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before...
More Alx Oncology Holdings Inc News

Company Profile

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia on April 1, 2020 and is headquartered in Burlingame, CA.

Head office United States
CEO Jason Lettmann
Employees 80
Founded 2015
Website www.alxoncology.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today